Endogenous sex steroid hormones and glucose in a South‐Asian population without diabetes: the Metabolic Syndrome and Atherosclerosis in South‐Asians Living in America pilot study by Needham, B. L. et al.
Research: Epidemiology
Endogenous sex steroid hormones and glucose in a South-
Asian population without diabetes: the Metabolic
Syndrome and Atherosclerosis in South-Asians Living in
America pilot study
B. L. Needham1, C. Kim2, B. Mukherjee3, P. Bagchi4, F. Z. Stanczyk5 and A. M. Kanaya6
1Department of Epidemiology and Center for Social Epidemiology and Population Health, University of Michigan, 2Departments of Medicine and Obstetrics and
Gynecology, University of Michigan, 3Department of Biostatistics, University of Michigan, 4Department of Statistics, University of Michigan, Ann Arbor, MI,
5Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA and 6Departments of Medicine, Epidemiology and Biostatistics,
University of California, San Francisco, CA, USA
Accepted 25 November 2014
Abstract
Aims To examine the associations between endogenous sex steroid hormones (oestradiol, testosterone and sex
hormone-binding globulin) with diabetes risk in a South-Asian population living in the USA.
Methods We used data from the Metabolic Syndrome and Atherosclerosis in South-Asians Living in America pilot
study. The analytical sample included 60 women and 45 men of Asian Indian origin living in the San Francisco Bay Area,
who were free from diabetes and cardiovascular disease and did not use exogenous sex steroids. Sex steroid hormone
levels were assessed by validated conventional radioimmunoassays, and visceral and hepatic adiposity were assessed by
computed tomography. We used multivariable regression to examine the association between endogenous sex steroid
hormone levels (log-transformed) and fasting glucose and 2-h glucose levels in a series of sex-stratified models adjusted
for age, waist circumference, visceral and hepatic adiposity, and insulin resistance.
Results In age-adjusted models, lower levels of sex hormone-binding globulin (b = 0.18, 95% CI 0.30, 0.06) and
higher levels of free testosterone (b = 0.14, 95% CI 0.02, 0.26) were associated with elevated fasting glucose levels in
South-Asian women, whereas lower levels of sex hormone-binding globulin (b = 0.14, 95% CI 0.26, 0.02) and
lower levels of total testosterone (b = 0.12, 95% CI 0.24, 0.00) were associated with elevated fasting glucose levels in
South-Asian men. Adjustment for waist circumference, visceral adiposity and insulin resistance attenuated most of these
associations, while adjustment for hepatic adiposity strengthened some of the observed associations. Similar results were
found for 2-h glucose levels.
Conclusions Results were consistent with previous research, which suggests that endogenous sex steroid hormones are a
risk factor for diabetes across multiple race/ethnic groups. Additional studies are needed to determine whether visceral
fat is a mediator or confounder of associations between sex steroid hormone and glucose levels.
Diabet. Med. 32, 1193–1200 (2015)
Introduction
The endogenous sex hormone profile of an individual,
consisting of oestradiol, testosterone and sex hormone-
binding globulin (SHBG), has emerged as a potential risk
factor for diabetes. Despite the high prevalence of diabetes
among South-Asian people in the USA [1], previous studies
have not considered whether sex steroid hormone levels are
associated with glucose levels in this population.
Using data from the Diabetes Prevention Program, we have
reported that changes in sex steroid hormone levels, as well
as their baseline levels, were associated with changes in
fasting and post-challenge glucose levels among postmeno-
pausal women [2,3]. In addition, multiple studies [4] have
found that lower levels of SHBG and higher levels of
testosterone and oestradiol were associated with an elevatedCorrespondence to: Belinda Needham. E-mail: needhamb@umich.edu.
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diabetes risk in women, whereas lower levels of testosterone
were associated with an elevated diabetes risk in men;
therefore, the relationship between sex steroid hormones and
diabetes appears to be sexually dimorphic.
Recent work in longitudinal cohorts suggests that adipos-
ity and sex steroid hormones in mid-life women are strongly
related, and this relationship may be bidirectional. In the
Study of Women’s Health Across the Nation (SWAN),
increases in waist circumference around the menopausal
transition predicted changes in SHBG, testosterone and
oestradiol [5]. At the same time, decreasing oestradiol also
predicted increases in waist circumference [5]. In SWAN, we
reported that SHBG was strongly associated with hepatic
adiposity, apart from waist circumference [6]; thus, assess-
ments of the impact of endogenous sex steroid hormones and
diabetes risk require adjustment for fat, optimally assessed
with more precise measures than anthropometry. This is of
particular importance in South-Asian people, who have
higher levels of visceral fat relative to BMI compared with
other racial/ethnic groups [7].
The aims of the present study were (1) to examine the
associations between endogenous sex steroid hormones and
fasting glucose and 2-h glucose levels in South-Asian women
and men without diabetes in the USA and (2) to determine
whether these associations were attenuated after adjusting
for waist circumference, visceral and hepatic adiposity, and
insulin resistance.
Patients and methods
Study population
The data used for the present study were from the Metabolic
Syndrome and Atherosclerosis in South-Asians Living in
America (MASALA) pilot study. From August 2006 to
October 2007, the study enrolled 150 community-dwelling
individuals (75 men and 75 women) living in the San
Francisco Bay area who self-identified as Asian Indian.
Participants were aged 45–84 years and had no known
cardiovascular disease. Detailed study methods have been
described elsewhere [8]. Briefly, this pilot study was popu-
lation-based, with random sampling of households in the San
Francisco Bay Area with South-Asian surnames from the
California Health Interview Survey. Subjects were eligible for
the study if they were free from physician-diagnosed cardio-
vascular disease (myocardial infarction, stroke, transient
ischaemic attack, congestive heart failure, angina, coronary
artery bypass graft surgery, percutaneous cardiovascular
interventions). Subjects were excluded if they could not
speak or understand Hindi or English, and, for the purposes
of this pilot study, people from other South-Asian countries
were excluded. Ninety-eight percent of respondents were
foreign-born. The Institutional Review Board at the Univer-
sity of California, San Francisco approved the study protocol
and all study subjects provided written informed consent. For
this analysis, we excluded people who used oestrogen
therapy and those who had known diabetes, leaving a total
of 60 women and 45 men.
Data collection
The study subjects were asked to provide blood samples after
a 12-h fast. Steroid hormones and SHBG levels were
measured at the Reproductive Endocrine Research Labora-
tory (University of Southern California). Oestradiol and
testosterone levels were quantified in serum (0.5 ml) using a
previously described radioimmunoassay method [9,10]. Prior
to radioimmunoassay, steroids were extracted with hexane:
ethyl acetate (3:2) and then oestradiol and testosterone were
separated from each other and their metabolites by Celite
column partition chromatography. The assay sensitivities for
the oestradiol and testosterone radioimmunoassays are 2 pg/
ml and 1.5 ng/dl, respectively. The interassay coefficients of
variation for these assays are 11, 13 and 12% at 15, 36 and
101 pg/ml, respectively, and 8, 12 and 12% at 13, 30
and 96 ng/dl, respectively. SHBG was measured using a
solid-phase, two-site chemiluminescent immunometric assay
on the Immulite Analyzer (Siemens Healthcare Diagnostics,
Deerfield, IL, USA). The SHBG assay sensitivity is 1 nmol/l
and the interassay coefficient of variation is < 10%. Free
oestradiol and testosterone were calculated using a validated
algorithm [11], based on derived equations [12], taking the
concentrations of total testosterone, total oestradiol and
SHBG into account and assuming a fixed albumin concen-
tration of 3.5 g/dl.
Fasting glucose was measured using a glucose oxidase
method. An oral glucose tolerance test was performed in
which blood samples for plasma glucose were taken 120 min
after participants consumed 75 g oral glucose solution.
Participant weight was determined using a digital scale,
height was measured with a stadiometer and waist circum-
ference was taken using a measuring tape halfway between
the lower ribs and the anterior superior iliac spine, at the site
of greatest circumference. Visceral and subcutaneous
What’s new?
• This is the first study to examine the associations
between sex steroid hormones and glucose levels in a
population-based sample of South-Asian people with-
out diabetes living in the USA.
• This work adds to a small body of literature examining
sex steroid hormones in South-Asian people, a popula-
tion at high risk for dysglycaemia.
• Although sex hormone-binding globulin has been
hypothesized to be a marker of hepatic adiposity,
associations of sex hormone-binding globulin with
glucose were not attenuated by hepatic adiposity.
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adiposity and hepatic liver-to-spleen attenuation ratio (values
< 1 represented higher amounts of hepatic fat) were mea-
sured using computed tomography (Philips Medical Systems,
Best, the Netherlands).Visceral and subcutaneous abdominal
fat were measured at the L4-L5 level after participants were
positioned supine. Non-enhanced computed tomography
images of liver and spleen density were used to quantify
hepatic fat content; a liver-to-spleen attenuation ratio of < 1
was used to define the presence of fatty liver. All computed
tomography scans were digitally recorded for batched
readings by a trained research assistant and intra-abdominal
adipose tissue area was quantified by delineating the intra-
abdominal cavity at the innermost aspect of the abdominal
and oblique muscle walls surrounding the cavity [13]. Fasting
serum insulin was measured by radioimmunoassay (Milli-
pore, St. Charles, MO, USA) and homeostatic model
assessment of insulin resistance was calculated as a proxy
measure of insulin resistance as
I0ðlIU=mlÞ G0ðmmol=lÞ=22:5;
where I0 is insulin and G0 is glucose [14]. Sociodemographic
characteristics, medical history and medication use were
assessed via questionnaire.
Statistical analysis
We used a series of sex-stratified multivariable regression
models to examine the association between endogenous sex
steroid hormones (log-transformed) and fasting glucose and
2-h glucose levels. Age, waist circumference, visceral and
hepatic adiposity, and insulin resistance were modelled as
continuous covariates. Model 1 was unadjusted for covari-
ates, model 2 adjusted for age, model 3 adjusted for age and
waist circumference, model 4 adjusted for age and visceral
adiposity, model 5 adjusted for age and hepatic adiposity,
model 6 adjusted for age and both visceral and hepatic
adiposity, model 7 adjusted for age and insulin resistance and
model 8 adjusted for age, insulin resistance, and visceral and
hepatic adiposity. All regression models were examined for
the presence of outliers and influential observations. The
analysis was completed using SAS version 9.3, SAS Institute,
Cary, NC, USA.
Results
Descriptive statistics stratified by sex are shown in Table 1.
Due to skewness, we examined median differences for the sex
steroid hormones and SHBG. For all other measures, we
examined mean differences. Age did not differ significantly
between women and men. Women had significantly lower
fasting glucose than men, but there was no sex difference in
2-h glucose levels. Women had significantly lower total
oestradiol, total testosterone, free oestradiol and free testos-
terone levels; whereas men had significantly lower SHBG
levels. Women had significantly lower visceral fat, but there
was no gender difference in waist circumference, continuous
liver-to-spleen attenuation ratio or BMI. When examining a
dichotomous measure of liver-to-spleen ratio, a higher
percentage of men had a ratio < 1, indicating higher amounts
of hepatic fat. Women had significantly lower homeostatic
model assessment of insulin resistance values than men.
As shown in Table 2, total testosterone was inversely
associated with fasting glucose levels among men but not
women, and this association was attenuated after adjusting
for waist circumference, visceral adiposity and insulin
resistance. SBHG was inversely associated with fasting
Table 1 Descriptive statistics for respondents without diabetes, stratified by sex
Women Men
Pn Mean (SD) Median (IQR) n Mean (SD) Median (IQR)
Age, years 61 55.78 (7.11) 56.05 (13.08) 45 58.06 (9.23) 56.77 (14.89) 0.39*
Fasting glucose, mmol/l 61 5.28 (0.57) 5.21 (0.53) 45 5.66 (0.53) 5.58 (0.63) < 0.001*
2-h glucose, mmol/l 61 7.00 (1.57) 6.72 (2.25) 45 7.41 (1.98) 7.83 (3.30) 0.30*
Total oestradiol, pmol/l 59 195.66 (362.95) 47.72 (47.72) 45 154.07 (44.48) 146.84 (54.15) < 0.001†
Total testosterone, nmol/l 59 0.88 (0.43) 0.76 (0.56) 45 18.82 (7.64) 17.64 (10.37) < 0.001†
SHBG, nmol/l 60 44.84 (25.01) 41.85 (26.40) 45 32.04 (15.91) 28.60 (15.90) < 0.001†
Free oestradiol, pmol/l 59 4.78 (9.21) 1.27 (1.06) 45 4.44 (1.28) 4.26 (1.62) < 0.001†
Free testosterone, nmol/l 59 0.18 (0.08) 0.16 (0.09) 45 4.80 (1.50) 4.56 (0.21) < 0.001†
Waist circumference, cm 61 93.77 (14.34) 90.2 (17.23) 45 96.62 (9.39) 95.3 (11.98) 0.06*
Visceral fat, per SD cm2 61 106.23 (42.65) 99.53 (56.15) 45 145.86 (53.38) 139.77 (80.17) < 0.001*
Liver-to-spleen attenuation ratio, HU 53 1.30 (0.20) 1.34 (0.22) 45 1.23 (0.18) 1.23 (0.17) 0.06*
Liver: spleen ratio < 1 53 8.20% 45 13.33% 0.00*
BMI, kg/m2 61 26.39 (5.30) 24.34 (5.65) 45 25.92 (4.10) 25.21 (5.14) 0.86*
HOMA-IR 61 2.26 (1.45) 2.02 (1.13) 45 3.28 (2.32) 2.51 (2.53) 0.01*
SHBG, sex hormone-binding globulin; HU, Hounsfield unit; HOMA-IR, homeostatic model assessment of insulin resistance.
*P value generated from t-test for sex comparison.
†P value generated from nonparametric Wilcoxon–Mann–Whitney test for sex comparison.
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glucose among both women and men. The association
among women was attenuated after adjusting for waist
circumference, visceral adiposity and insulin resistance;
whereas adjusting for hepatic adiposity strengthened the
association. Among men, the association between SHBG and
fasting glucose was partially attenuated after adjusting for
visceral adiposity and insulin resistance. Free testosterone
was positively associated with fasting glucose among women
but not men. This association was partially attenuated after
adjusting for waist circumference, visceral adiposity and
insulin resistance. There was no association between oestra-
diol or free oestradiol and fasting glucose levels for either
women or men. As shown in Table 3, similar results were
obtained for 2-h glucose.
Discussion
In this study in a middle-aged Asian Indian population
without diabetes, living in the San Francisco Bay Area, a
population at high-risk for dysglycaemia, we found that
Table 2 Associations of sex steroid hormones (log-transformed) with fasting glucose (mmol/l) in respondents without diabetes, stratified by sex
Women Men
n b Lower Upper P n b Lower Upper P
Association with total oestradiol
Model 1 59 0.01 0.13 0.11 0.86 45 0.08 0.20 0.04 0.19
Model 2 59 0.02 0.14 0.10 0.80 45 0.08 0.20 0.04 0.19
Model 3 59 0.02 0.14 0.10 0.74 45 0.08 0.21 0.04 0.17
Model 4 59 0.04 0.16 0.08 0.52 45 0.07 0.19 0.05 0.24
Model 5 51 0.03 0.15 0.09 0.65 45 0.08 0.20 0.04 0.18
Model 6 51 0.04 0.16 0.09 0.56 45 0.07 0.19 0.05 0.27
Model 7 59 0.01 0.13 0.11 0.90 45 0.05 0.17 0.07 0.42
Model 8 51 0.02 0.14 0.11 0.80 45 0.03 0.16 0.09 0.57
Association with total testosterone
Model 1 59 0.04 0.08 0.16 0.49 45 0.13 0.26 0.01 0.03
Model 2 59 0.04 0.08 0.16 0.49 45 0.12 0.24 0.00 0.05
Model 3 59 0.05 0.07 0.17 0.44 45 0.11 0.23 0.01 0.07
Model 4 59 0.05 0.07 0.17 0.38 45 0.09 0.21 0.03 0.14
Model 5 51 0.03 0.09 0.15 0.67 45 0.12 0.24 0.00 0.05
Model 6 51 0.05 0.08 0.17 0.45 45 0.09 0.21 0.03 0.16
Model 7 59 0.05 0.07 0.17 0.41 45 0.03 0.15 0.09 0.64
Model 8 51 0.04 0.08 0.16 0.50 45 0.03 0.16 0.09 0.57
Association with SHBG
Model 1 60 0.18 0.30 0.06 0.01 45 0.17 0.29 0.05 0.01
Model 2 60 0.18 0.30 0.06 0.01 45 0.14 0.26 0.02 0.03
Model 3 60 0.08 0.20 0.04 0.18 45 0.13 0.25 0.01 0.04
Model 4 60 0.11 0.23 0.01 0.07 45 0.11 0.23 0.01 0.08
Model 5 52 0.24 0.36 0.12 0.00 45 0.14 0.26 0.01 0.03
Model 6 52 0.17 0.29 0.05 0.01 45 0.10 0.22 0.02 0.09
Model 7 60 0.01 0.13 0.11 0.87 45 0.05 0.17 0.07 0.38
Model 8 52 0.05 0.17 0.08 0.46 45 0.06 0.18 0.06 0.34
Association with free oestradiol
Model 1 59 0.01 0.11 0.13 0.68 45 0.02 0.14 0.10 0.35
Model 2 59 0.01 0.11 0.13 0.71 45 0.04 0.16 0.08 0.32
Model 3 59 0.01 0.13 0.11 0.70 45 0.05 0.17 0.07 0.30
Model 4 59 0.02 0.15 0.10 0.71 45 0.05 0.17 0.07 0.31
Model 5 51 0.00 0.12 0.12 0.74 45 0.04 0.16 0.08 0.35
Model 6 51 0.02 0.14 0.10 0.73 45 0.04 0.16 0.08 0.34
Model 7 59 0.01 0.13 0.11 0.88 45 0.04 0.17 0.08 0.54
Model 8 51 0.01 0.13 0.11 0.86 45 0.02 0.14 0.10 0.73
Association with free testosterone
Model 1 59 0.14 0.02 0.26 0.03 45 0.09 0.21 0.03 0.14
Model 2 59 0.14 0.02 0.26 0.02 45 0.10 0.22 0.02 0.11
Model 3 59 0.09 0.03 0.21 0.13 45 0.09 0.21 0.03 0.15
Model 4 59 0.11 0.01 0.23 0.07 45 0.07 0.19 0.05 0.27
Model 5 51 0.13 0.01 0.25 0.03 45 0.10 0.22 0.02 0.11
Model 6 51 0.12 0.00 0.24 0.06 45 0.06 0.18 0.06 0.30
Model 7 59 0.05 0.07 0.17 0.90 45 0.01 0.14 0.11 0.82
Model 8 51 0.06 0.06 0.18 0.33 45 0.02 0.14 0.11 0.78
SHBG, sex hormone-binding globulin.
Model 1: unadjusted association; model 2: adjusted for age; model 3: adjusted for age and waist circumference; model 4: adjusted for age and
visceral fat; model 5: adjusted for age and hepatic adiposity; model 6: adjusted for age, visceral fat and hepatic adiposity; model 7: adjusted
for age and insulin resistance; model 8: adjusted for age, insulin resistance and visceral and hepatic adiposity.
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endogenous sex steroid hormone profile was cross-section-
ally associated with both fasting and post-challenge 2-h
glucose levels, and the nature of this association differed
according to sex. Associations were most robust for SHBG,
with lower levels of SHBG associated with higher levels of
glucose in both men and women. Adjustment for visceral
adiposity attenuated this relationship (more so for women
than men), while adjustment for hepatic adiposity tended to
strengthen this relationship. While lower total testosterone
was associated with significantly higher fasting and 2-h
glucose levels in men, total testosterone was not associated
with glucose levels in women. Adjustment for visceral fat
partially attenuated this relationship. Oestradiol, in either
total or free form, was not associated with fasting or 2-h
glucose levels in men or women before or after adjustment
for adiposity. These patterns of associations parallel those in
other racial/ethnic groups at lower risk of diabetes [4],
despite the differences in fat deposition that distinguish
South-Asian people.
The South-Asian population has been characterized as
having higher glucose levels in relation to body fat compared
with other racial/ethnic groups [15]. In a comparison of a
Table 3 Associations of sex steroid hormones (log-transformed) with 2-h glucose (mmol/l) in respondents without diabetes, stratified by sex
Women Men
n b Lower Upper P n b Lower Upper P
Association with total oestradiol
Model 1 59 0.03 0.15 0.09 0.67 45 0.05 0.17 0.08 0.46
Model 2 59 0.04 0.16 0.08 0.56 45 0.05 0.17 0.07 0.43
Model 3 59 0.04 0.16 0.08 0.54 45 0.06 0.18 0.06 0.33
Model 4 59 0.05 0.17 0.07 0.37 45 0.03 0.16 0.09 0.57
Model 5 51 0.04 0.16 0.08 0.54 45 0.07 0.19 0.05 0.26
Model 6 51 0.04 0.16 0.08 0.48 45 0.05 0.17 0.07 0.41
Model 7 59 0.02 0.14 0.10 0.71 45 0.02 0.14 0.10 0.72
Model 8 51 0.03 0.15 0.09 0.63 45 0.03 0.15 0.09 0.59
Association with total testosterone
Model 1 59 0.09 0.21 0.03 0.13 45 0.14 0.26 0.02 0.03
Model 2 59 0.10 0.22 0.02 0.12 45 0.16 0.28 0.03 0.01
Model 3 59 0.10 0.22 0.02 0.11 45 0.12 0.24 0.01 0.06
Model 4 59 0.09 0.21 0.03 0.14 45 0.10 0.22 0.03 0.12
Model 5 51 0.07 0.19 0.05 0.28 45 0.15 0.28 0.03 0.01
Model 6 51 0.06 0.18 0.06 0.34 45 0.10 0.23 0.02 0.09
Model 7 59 0.09 0.21 0.03 0.14 45 0.09 0.21 0.03 0.13
Model 8 51 0.05 0.17 0.07 0.39 45 0.08 0.20 0.04 0.20
Association with SHBG
Model 1 60 0.18 0.30 0.06 0.00 45 0.13 0.25 0.01 0.04
Model 2 60 0.18 0.30 0.06 0.00 45 0.19 0.31 0.07 0.00
Model 3 60 0.15 0.27 0.03 0.02 45 0.15 0.27 0.03 0.01
Model 4 60 0.14 0.26 0.02 0.03 45 0.14 0.26 0.02 0.03
Model 5 52 0.18 0.30 0.05 0.01 45 0.20 0.32 0.07 0.00
Model 6 52 0.12 0.24 0.00 0.05 45 0.15 0.27 0.03 0.02
Model 7 60 0.10 0.22 0.02 0.11 45 0.14 0.26 0.01 0.03
Model 8 52 0.06 0.18 0.06 0.30 45 0.13 0.25 0.01 0.04
Association with free oestradiol
Model 1 59 0.00 0.12 0.12 0.95 45 0.00 0.13 0.12 0.94
Model 2 59 0.01 0.13 0.11 0.88 45 0.01 0.11 0.13 0.88
Model 3 59 0.02 0.14 0.10 0.72 45 0.02 0.14 0.10 0.73
Model 4 59 0.04 0.16 0.08 0.52 45 0.00 0.13 0.12 0.94
Model 5 51 0.01 0.13 0.11 0.82 45 0.01 0.13 0.11 0.87
Model 6 51 0.03 0.15 0.09 0.63 45 0.02 0.14 0.11 0.79
Model 7 59 0.03 0.15 0.09 0.65 45 0.00 0.13 0.12 0.95
Model 8 51 0.02 0.14 0.10 0.77 45 0.01 0.11 0.14 0.82
Association with free testosterone:
Model 1 60 0.00 0.12 0.12 0.94 45 0.12 0.24 0.00 0.05
Model 2 60 0.00 0.12 0.12 0.97 45 0.12 0.24 0.00 0.05
Model 3 60 0.03 0.15 0.09 0.61 45 0.09 0.21 0.04 0.16
Model 4 60 0.03 0.15 0.09 0.65 45 0.06 0.18 0.06 0.30
Model 5 52 0.02 0.10 0.14 0.77 45 0.12 0.24 0.00 0.06
Model 6 52 0.20 0.41 0.00 0.96 45 0.07 0.19 0.05 0.26
Model 7 59 0.05 0.17 0.07 0.41 45 0.06 0.18 0.06 0.31
Model 8 51 0.03 0.15 0.09 0.66 45 0.05 0.17 0.08 0.45
SHBG, sex hormone-binding globulin.
Model 1: unadjusted association; model 2: adjusted for age; model 3: adjusted for age and waist circumference; model 4: adjusted for age and
visceral fat; model 5: adjusted for age and hepatic adiposity; model 6: adjusted for age, visceral fat and hepatic adiposity; model 7: adjusted
for age and insulin resistance; model 8: adjusted for age, insulin resistance and visceral and hepatic adiposity.
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larger US South-Asian cohort with that of the Multi-Ethnic
Study of Atherosclerosis (MESA), a US cohort of mid-life
adults, South-Asian people had a lower BMI and waist
circumference than non-Hispanic white, African-American
and Latino people, but a higher prevalence of Type 2
diabetes [15,16]. One explanation for this risk difference is
that, despite their smaller body size, South-Asian people have
a higher amount of visceral fat relative to overall body mass.
In a 2013 review, Bhopal [17] noted that South-Asian people
have lower birth weight and excess caloric intake in
childhood and young adulthood compared with Northern
Europeans, resulting in relatively greater ectopic fat deposi-
tion, which increases diabetes risk to a greater extent than
does subcutaneous fat deposition [18]. This fat deposition is
exacerbated by poor ongoing lifestyle behaviours. Immi-
grants may be at particular risk for these poor behaviours
and additional stresses: in one cross-sectional examination of
South-Asian people (consisting of people from India and
Pakistan) in Kuwait, the prevalence of diabetes and other
cardiovascular risk factors was higher compared with South-
Asian people in their native countries [19]. Heald et al. [20]
compared Gujarati men in India with men from the same
villages living in the UK and found that migrants had higher
waist circumferences compared with non-migrants, despite
the younger age of the migrants.
Endogenous sex steroid hormones may be a possible
mediator of the effect of this relative excess of ectopic fat on
carbohydrate metabolism because of the actions of these
hormones on skeletal muscle as well as on hepatic glucose
metabolism [4]. Previous research examining sex steroid
hormone levels among South-Asian people has shown that
immigrant British Pakistani women had a significantly higher
free androgen index than British-born Pakistani women and
women of European origin [21], while South-Asian men in
the UK had lower total testosterone levels than men of
European origin [22]. Heald et al. [20] reported that higher
levels of SHBG and higher levels of testosterone were
correlated with waist circumference and higher insulin
sensitivity in both migrant and non-migrant Indian popula-
tions in the UK. In the USA, the relationship between SHBG
and waist circumference has been reported in children of
South-Asian origin [23], but not among adults. We are not
aware of any previous studies examining the relationship
between sex hormone profiles and fasting or post-challenge
glucose levels in South Asians in the USA. Studies in other
races/ethnic populations [4,24] have reported fairly consis-
tent relationships between lower levels of SHBG and lower
levels of glucose in both men and women, while higher levels
of testosterone relative to oestradiol are related to lower
glucose levels in men and an inverse, weaker relationship is
observed in women. Our results are consistent with this
previous work and extend it to the population of South-
Asian migrants in the USA.
Aside from the MASALA study, we are not aware of any
other studies in South-Asian populations that have data on
sex hormones and ectopic fat deposition assessed by radio-
graphic imaging. In other racial/ethnic populations, endog-
enous sex steroids in mid-life adults have been variably
associated with glucose after consideration of visceral fat,
although there are relatively few studies that have used
imaging to measure fat mass. Peter et al. [24] noted that
SHBG was correlated with fasting glucose levels, and this
association was significant but somewhat attenuated after
adjustment for hepatic fat; visceral fat was correlated with
SHBG to a significantly lesser extent than hepatic fat. By
contrast, Tschernof et al. [25] found that SHBG was not
related to metabolic syndrome components, including glu-
cose, after adjustment for visceral fat. Bonnet et al. [26]
reported that the relationship between SHBG and fasting
glycaemia was no longer significant after adjustment for
hepatic fat, suggesting that SHBG, a protein produced by the
liver, was a marker for hepatic fat. While our results are
similar to other studies that found that adjustment for
visceral fat on computed tomography generally attenuated
relationships between sex steroid hormones and glucose, our
results are conflicting in that adjustment for hepatic fat in the
MASALA population tended to strengthen associations.
These results suggest that SHBG has a different relationship
with hepatic fat than that observed in other racial/ethnic
groups but this should be interpreted with caution because of
the small sample size and the risk of a type I error associated
with multiple testing.
Post-challenge glucose is commonly believed to reflect
skeletal muscle insulin sensitivity and later-phase insulin
release, and is subject to greater intra-individual variation
than fasting glucose [27]. We have previously reported
weaker associations between changes in endogenous sex
steroid hormone levels and changes in 2-h as opposed to
fasting glucose levels [2]. Among participants in the pilot
MASALA study, patterns of association were similar
between sex hormones and fasting and 2-h glucose levels,
which may reflect the cross-sectional nature of the associa-
tions or stronger relationships between these hormones and
post-challenge glucose levels than previously observed in
other populations.
The present report has several strengths and limitations.
First, we examined cross-sectional data, so we were unable to
determine whether baseline sex steroid hormone levels were
associated with changes over time in fasting and 2-h glucose.
Longitudinal data could provide stronger evidence for a
causal association between sex steroid hormones and glu-
cose, and would facilitate an examination of associations
between these hormones and incident diabetes. Next, we did
not adjust for multiple comparisons. Thus, some of the
findings reported here may be attributable to chance and
should be interpreted with caution; however, given the small
sample size, we had limited power to detect associations. In
the future, this work could be extended to the larger
MASALA study (n = 906) with the addition of sex steroid
hormone data.
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A key strength of the present study was its examination
of a population-based sample of Asian Indians in the USA,
an understudied and rapidly growing minority group with
elevated risk of diabetes. Other strengths include adjust-
ment for multiple measures of adiposity, including waist
circumference and visceral and hepatic adiposity, and the
inclusion of women and men, which allowed us to examine
gender differences in associations between sex steroid
hormones and glucose.
Learning more about the aetiology of glucose intolerance
in the South-Asian population is important, as this may
suggest racial/ethnic group-specific pathways for prevention
and treatment. This study suggests that endogenous sex
hormone profile is a risk factor for dysglycaemia in a
population-based sample of US-dwelling South-Asian people
in mid- to late life. Results were generally consistent with
findings in other racial/ethnic groups; however, multi-ethnic
studies are needed to determine whether sex steroid
hormones are more strongly associated with glucose in
South-Asian populations compared with other groups and
whether sex steroid hormones contribute to the higher
prevalence of diabetes among South-Asian people in the
USA compared with African-American, Latino, Native
American and non-Hispanic white people [1].
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